Peter Attia's Medicine 3.0: The Evidence Behind the Longevity Framework
Peter Attia is a physician, former surgical oncology resident, and the author of Outlive: The Science and Art of Longevity - the most commercially successful longevity book published in the past decade. His Medicine 3.0 framework represents a systematic attempt to apply the principles of preventive medicine decades earlier than conventional medicine currently does. This is an evidence-calibrated assessment of the framework's strongest and weakest elements.
- Medicine 3.0 is Attia's framework for preventive medicine that applies evidence-based tools decades earlier than conventional Medicine 2.0, which focuses primarily on treating disease after it manifests. The core insight - that the diseases killing most people begin 15 to 30 years before symptoms appear and should be addressed in the third and fourth decades of life - is well-supported by the science.
- Attia's emphasis on the four 'horsemen' (cardiovascular disease, cancer, neurodegenerative disease, and metabolic disease) as the primary longevity targets, and his framework of addressing their root causes (ApoB lowering, insulin resistance reversal, muscle maintenance, sleep optimization) rather than their downstream consequences, is evidence-aligned and clinically sensible.
- The strongest elements of the Attia framework: the emphasis on VO2 max and muscle strength as primary longevity biomarkers, aggressive LDL/ApoB lowering initiated early, comprehensive metabolic assessment beyond HbA1c, and the integration of psychological health as a longevity variable at least as important as physical health.
- The more contested elements: the use of continuous glucose monitoring in metabolically healthy individuals (debated in endocrinology), the broad off-label use of rapamycin and other pharmacological interventions without human longevity RCT evidence, and the emphasis on testosterone optimization for men that some physicians consider more aggressive than established evidence supports.
- The most universally applicable lessons from the Attia framework, regardless of resource level: test ApoB, Lp(a), fasting insulin, and HOMA-IR as standard (not just LDL-C); train VO2 max and grip strength as primary longevity fitness targets; begin aggressive preventive intervention in your 30s and 40s rather than waiting for disease to manifest; and treat psychological distress as a longevity threat equal to metabolic risk.
Peter Attia trained as a surgeon at Johns Hopkins and completed a surgical oncology fellowship at the NIH before transitioning to longevity medicine. His book Outlive: The Science and Art of Longevity (2023) became one of the best-selling health books of the decade, reaching a mainstream audience with concepts that had previously circulated primarily within specialist longevity medicine circles. His Medicine 3.0 framework deserves evaluation on its merits - which are substantial but not uniform.1
The Medicine 3.0 Framework
Attia distinguishes three phases of medicine: Medicine 1.0 (pre-scientific, based on intuition and tradition), Medicine 2.0 (evidence-based medicine focused on treating disease after it manifests, using population-level statistics to guide individual treatment decisions), and Medicine 3.0 (his proposed paradigm, which applies precision medicine tools and aggressive preventive interventions decades before disease manifests, individualized to the specific patient's risk factors, biomarkers, and goals).2
The core critique of Medicine 2.0 that motivates the framework is well-founded: most of the diseases that kill people in developed countries - cardiovascular disease, cancer, type 2 diabetes, Alzheimer's disease - begin accumulating pathology 15 to 30 years before symptoms appear or clinical diagnosis is made. Conventional medicine typically intervenes at or after diagnosis. Attia argues that waiting for diagnosis before intervening is analogous to waiting until a house is burning to buy fire insurance - and that the evidence supports beginning aggressive preventive intervention in the third and fourth decades of life.
The Four Horsemen: Attia's Longevity Targets
Attia frames longevity medicine around four conditions he terms the Four Horsemen: atherosclerotic cardiovascular disease, cancer, neurodegenerative disease, and metabolic dysfunction. His argument is that these four conditions account for the vast majority of mortality in developed countries, that they share common upstream risk factors (insulin resistance, chronic inflammation, elevated ApoB, sleep deprivation, physical inactivity), and that addressing these upstream factors aggressively represents the highest-leverage longevity strategy available. This framing is both accurate and clinically useful - it redirects attention from managing downstream disease to identifying and correcting upstream drivers.3
What the Attia Framework Gets Right
ApoB and Lp(a) as primary lipid biomarkers: Attia was among the first popular communicators to clearly explain why ApoB is more informative than LDL-C and why Lp(a) measurement is essential in a complete cardiovascular risk assessment. Both positions are well-supported by the current evidence and represent an advance over standard of care. VO2 max and grip strength as primary fitness biomarkers: The emphasis on cardiorespiratory fitness and muscular strength rather than body weight or BMI as the primary fitness-related longevity variables is strongly evidence-aligned. Metabolic assessment beyond HbA1c: The inclusion of fasting insulin, HOMA-IR, uric acid, and advanced lipid panels in metabolic assessment goes beyond standard care and is supported by the evidence on early metabolic dysfunction detection. Psychological health as a longevity variable: Attia's explicit inclusion of psychological wellbeing, trauma, and emotional regulation as longevity variables equal in importance to physical health metrics is a valuable and underemphasized contribution - consistent with the substantial epidemiological literature on stress, depression, and mortality.4
Where the Framework Is More Contested
Off-label rapamycin use: Attia personally takes rapamycin intermittently for longevity purposes and discusses it extensively. The animal evidence is extraordinary. The human longevity evidence is absent. For a physician-communicator who emphasizes evidence-based medicine, this represents a meaningful inconsistency between framework and practice. CGM in metabolically healthy adults: Attia advocates for CGM use in non-diabetic adults, which is defensible as a personalized nutrition tool but contested as a clinical recommendation in mainstream endocrinology. Aggressive testosterone optimization: Attia's approach to testosterone in men is more proactive than many endocrinologists would practice, though the TRAVERSE trial has improved the evidence base for TRT safety. Extensive supplement protocols: Some of Attia's supplement recommendations extend beyond the current evidence for specific supplements in longevity-oriented healthy adults.5
The Universally Applicable Lessons
The most valuable contributions of the Attia framework do not require a 2-million-dollar-per-year budget or access to specialized longevity clinics. They are: (1) Know your ApoB, Lp(a), fasting insulin, and HOMA-IR - not just your LDL-C. (2) Treat VO2 max and grip strength as primary health biomarkers, not secondary ones. (3) Begin serious preventive investment in your 30s rather than your 50s - most of the diseases killing people are seeded decades before they manifest. (4) Psychological health is not a separate category from physical longevity - it is one of its primary determinants. (5) Cardiorespiratory fitness is the most powerful longevity lever available to most people, and most people are dramatically underinvesting in it.
References
- 1Attia P, Gifford B. "Outlive: The Science and Art of Longevity." Harmony Books. 2023. [PubMed]
- 2Sniderman AD, et al. "Why is precision medicine considered the future of medicine? NPJ Precision Oncology. 2018;2(1):1.
- 3Khaw KT, et al. "Combined impact of health behaviours and mortality in men and women." PLoS Medicine. 2008;5(1):e12. [PubMed]
- 4Mandsager K, et al. "Association of cardiorespiratory fitness with long-term mortality." JAMA Network Open. 2018;1(6):e183605. [PubMed]
- 5Lincoff AM, et al. "Cardiovascular safety of testosterone-replacement therapy (TRAVERSE)." NEJM. 2023;389(2):107-117. [PubMed]